Harpoon Therapeutics Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Harpoon Therapeutics's estimated annual revenue is currently $4.8M per year.
- Harpoon Therapeutics received $70.0M in venture funding in November 2018.
- Harpoon Therapeutics's estimated revenue per employee is $71,970
- Harpoon Therapeutics's total funding is $223.2M.
- Harpoon Therapeutics has 66 Employees.
- Harpoon Therapeutics grew their employee count by 27% last year.
- Harpoon Therapeutics currently has 7 job openings.
|Mark Wesson||Director, CMC Outsourcing|
|Phyllis Kimmel||Administrative Manager|
|Natalie Sacks||Chief Medical Officer|
|Suresh Pullela||Senior Director Quality Assurance|
|Che-Leung Law||VP, Translational Medicine|
|Rupak Neupane||Senior Manager, Corporate Analytics|
|Georgia Erbez||Chief Financial Officer|
|Christopher Whitmore||Vice President Finance|
|Rachael Lester||VP Corporate Development|
|Jack Lin||Director, New Technologies|
What Is Harpoon Therapeutics?
Harpoon Therapeutics is a clinical stage biotechnology company co-founded by Patrick Bauerle, a pioneer in T-cell engagement, and Luke Evnin (MPM Capital) in 2015 to develop and commercialize a novel class of T cell recruiting antibodies engage a patient's own immune cells to fight cancer and other diseases. The world-class team of protein engineers and immunologists at Harpoon have built upon the successful development of the bispecific (BiTE or bispecific T cell engager) antibody Blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. Harpoon's tri-specific T-cell redirection platform -- TriTAC -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, CAR-T and other T-cell engaging approaches by improving activity against solid tumors convenience of administration treatment of more tumor types and other immunologic diseases. Harpoon has discovered proprietary drug candidates and has an expansive research portfolio leveraging the TriTAC platform. Harpoon plans to file its first 2 INDs and initiate its first clinical study in 2018. Harpoon Therapeutics recently completed a Series B financing round with investors: MPM Capital, New Leaf Venture Partners, Arix Biosciences, and Taiho Ventures.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|ZO Skin Health||$59.3M||295||2%||N/A|
Harpoon Therapeutics News
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage ...
Harpoon Therapeutics Inc (HARP) stock has fallen -2.14% since Thursday, February 7, 2019 when Harpoon Therapeutics Inc began trading.
In its latest trading session, Harpoon Therapeutics, Inc. (HARP) dropped by -1.0% – here is what that looked like (as of 2019-09-06): ...
Harpoon Therapeutics Funding
Harpoon Therapeutics Executive Hires
|2017-05-05||Che-Leung Law||VP TRANSLATIONAL MEDICINE||Article|
|2017-10-27||Susan Jones||SVP product development||Article|
|2018-09-19||Chris Whitmore||VP Finance||Article|
|2018-10-04||Natalie Sacks||Chief Medical Officer||Article|
|2018-10-31||Georgia Erbez||Chief Financial Officer||Article|